Novo Nordisk this week presented an expansive plan to investors aimed at spurring growth beyond its marquee obesity and diabetes medications Wegovy and Ozempic, which face patent expiration in major markets in the early 2030s. The company detailed a pipeline intended to broaden its product portfolio beyond its traditional focus areas. However, Wall Street responded negatively to the presentation, with stock declines reflecting investor disappointment over growth projections that aligned with overall industry benchmarks rather than exceeding them, and concerns about the absence of near-term recovery details.
Meanwhile, Eli Lilly has been steadily capturing market share from its Danish rival, particularly in the emerging oral weight loss medication category. Novo maintains an early advantage following its launch of the Wegovy pill, which preceded Lilly’s competing pill Foundayo by several months. Novo’s chief executive indicated that preliminary data suggests patients may have been seeking injectable alternatives, potentially positioning pills as the dominant delivery method by decade’s end.
Lilly, however, is leveraging substantial commercial resources to accelerate Foundayo’s uptake. Company leadership reported that roughly one-third of new patients starting GLP-1 pills are selecting Lilly’s product, with oral market share expanding on a weekly basis. Following the federal government’s July decision to extend Medicare coverage to obesity medications, Lilly has secured significant early penetration, with company executives noting that approximately 70% of the 700,000 seniors who initiated GLP-1 therapy through Medicare selected Lilly products. Market data from August indicated Lilly held approximately 61% of the total U.S. GLP-1 market in the second quarter, compared to Novo’s roughly 39%.
Analysts attribute Lilly’s advantages to its superior commercial capabilities, global expansion initiatives, and robust pipeline development. Foundayo, as a small-molecule drug, may offer manufacturing scalability benefits over peptide-based competitors, potentially supporting long-term cost advantages. Looking ahead, Lilly is advancing next-generation candidates including retatrutide, a triple-agonist therapy demonstrating superior weight loss results in clinical trials, with regulatory approval anticipated in the first quarter of 2027.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI